Biocon Biologics, subsidiary of Biocon, announced a settlement and license agreement with Amgen Inc. that clears the path for the commercialization of Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq) in the United States.
Bosaya™ 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso™ 120 mg/1.7 mL (70 mg/mL injection for subcutaneous use in a single-dose vial, are biosimilars to Amgen's Prolia® and Xgeva®, respectively. These products are used in the treatment of osteoporosis and cancer-related bone conditions.
Biocon Biologics and Amgen executed the settlement agreement to resolve the pending patent litigation at the United States District Court for the District of New Jersey.
The agreement enables Biocon Biologics to launch BOSAYA and AUKELSO in the U.S. from October 1, 2025. The other terms of the settlement remain confidential.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."